Sugi Predict

Sugi Predict / Compounds / SCHEMBL735122

SCHEMBL735122

SCHEMBL735122

Cc1c[nH]c2ccc(C(F)(F)F)cc12

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KIF11 P52732 4/20 0.54
▸ HTR1A P08908 1/20 0.48
▸ DRD2 P14416 1/20 0.48
▸ HTR7 P34969 1/20 0.48
▸ HTR6 P50406 1/20 0.48
▸ MEN1 O00255 3/20 0.47
▸ KMT2A Q03164 3/20 0.47
▸ ATM Q13315 1/20 0.47
▸ IDO1 P14902 1/20 0.47
▸ KDM4E B2RXH2 1/20 0.44
▸ MAPT P10636 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ ALOX12 P18054 1/20 0.42
▸ CHUK O15111 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ HTR1D P28221 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2972627 0.85 HSD17B10 (0.53) KIF11MEN1KMT2AATMMAPT
SCHEMBL12012858 0.83 HTR1D (0.57) KIF11HTR1AATMALDH1A1HPGD
SCHEMBL29609054 0.79 KIF11 (0.49) KIF11HTR1ADRD2HTR7HTR6
SCHEMBL27946710 0.78 KIF11 (0.47) KIF11HTR1ADRD2HTR7HTR6
SCHEMBL15723618 0.77 THRA (0.46) KIF11HTR1ADRD2HTR7HTR6
SCHEMBL2056337 0.77 HTR1D (0.51) KIF11HTR1ADRD2HTR7HTR6
SCHEMBL17027274 0.75 IDO1 (0.48) KIF11HTR1ADRD2HTR7HTR6
SCHEMBL16619064 0.75 PBRM1 (0.54) KIF11HTR1ADRD2HTR7HTR6
SCHEMBL26674885 0.75 HTR1D (0.52) KIF11HTR1ADRD2HTR7HTR6
SCHEMBL17026963 0.75 KMT2A (0.50) KIF11HTR1ADRD2HTR7HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118955574-B Phosphorescent iridium complex, luminescent material and organic electroluminescent device 季华实验室 2025-04-29 — — CN disclosed
CN-118955574-A Phosphorescent iridium complex, luminescent material and organic electroluminescent device 季华实验室 2024-11-15 — — CN disclosed
WO-2023116915-A1 ACHE/SERT DUAL-TARGET INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF 珠海市藤栢医药有限公司 2023-06-29 — — WO disclosed
US-9789089-B2 Therapeutic compounds GILEAD SCIENCES, INC. (US) 2017-10-17 — — US disclosed
US-20170137405-A1 COMPOUNDS FOR THE TREATMENT OF HIV GILEAD SCIENCES, INC. 2017-05-18 — — US disclosed
US-9540343-B2 Compounds for the treatment of HIV GILEAD SCIENCES, INC. (US) 2017-01-10 — — US disclosed
EP-2943487-B1 5-MEMBERED HETEROARYLS AND THEIR USE AS ANTIVIRAL AGENTS GILEAD SCIENCES INC (US) 2016-11-16 — — EP disclosed
EP-2697232-B1 6,7-DIHYDROIMIDAZO[2,1-B][1,3]OXAZINE BACTERICIDES OTSUKA PHARMA CO LTD (JP) 2016-05-18 — — EP disclosed
US-20160067224-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2016-03-10 — — US disclosed
US-9220710-B2 Therapeutic compounds GILEAD SCIENCES, INC. (US) 2015-12-29 — — US disclosed
US-8258130-B2 Pyrimidine hydrazide compounds as PGDS inhibitors SANOFI (FR) 2012-09-04 — — US disclosed
EP-2475642-A1 USE OF INDOLE DERIVATIVES AS NURR-1 ACTIVATORS FOR THE APPLICATION THEREOF AS A MEDICAMENT FOR THE TREATMENT OF PARKINSON'S DISEASE Laboratoires Fournier S.A. (FR) 2012-07-18 — — EP disclosed
US-8138187-B2 Substituted heteroaryl derivatives GRUENENTHAL GMBH (DE) 2012-03-20 — — US disclosed
US-7977370-B2 (Hetero)aryl cyclohexane derivatives GRUENENTHAL GMBH (DE) 2011-07-12 — — US disclosed
WO-2011030068-A1 USE OF INDOLE DERIVATIVES AS NURR-1 ACTIVATORS FOR THE APPLICATION THEREOF AS A MEDICAMENT FOR THE TREATMENT OF PARKINSON'S DISEASE LABORATOIRES FOURNIER SA (FR) 2011-03-17 — — WO disclosed
US-20100048568-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI-AVENTIS (FR) 2010-02-25 — — US disclosed
US-20100009986-A1 SUBSTITUTED HETEROARYL DERIVATIVES GRUNENTHAL GMBH (DE) 2010-01-14 — — US disclosed
EP-2142516-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS Sanofi-Aventis (FR) 2010-01-13 — — EP disclosed
US-20090247573-A1 (HETERO)ARYL CYCLOHEXANE DERIVATIVES GRUNENTHAL GMBH (DE) 2009-10-01 — — US disclosed
WO-2008121670-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI-AVENTIS (FR) 2008-10-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247573-A1 (HETERO)ARYL CYCLOHEXANE DERIVATIVES OPRL1, OPRM1, OPRD1 KIF11 4356/4885HTR1A 18/4885DRD2 215/4885
US-20100009986-A1 SUBSTITUTED HETEROARYL DERIVATIVES CYP3A43, HMGCR, ABCG2 KIF11 4521/4885HTR1A 746/4885DRD2 553/4885
US-20160067224-A1 THERAPEUTIC COMPOUNDS HAVCR2, SARS1, G6PD KIF11 3164/4885HTR1A 4414/4885DRD2 4212/4885
US-20100048568-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS HRH2, HRH1, HRH4 KIF11 2924/4885HTR1A 215/4885DRD2 472/4885
US-20170137405-A1 COMPOUNDS FOR THE TREATMENT OF HIV CCR5, NPC1, FURIN KIF11 2398/4885HTR1A 4710/4885DRD2 4227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.